Jak2v617f | List of Frontiers open access articles

Case Report

Published on 26 Oct 2022

Ropeginterferon-alfa2b resolves angina pectoris and reduces JAK2V617F in a patient with clonal hematopoiesis of indeterminate potential: A case report

in Hematopoiesis and Stem Cells

Miklos Egyed
Bela Kajtar
Csaba Foldesi
Vibe Skov
Lasse Kjær
Hans Carl Hasselbalch

Frontiers in Hematology

doi 10.3389/frhem.2022.1005666

2,176 views
3 citations

PDF-read only

Review

Published on 02 Oct 2018

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance

Saeid Shahrabi
Ali Ehsanpour
Somayyeh Heidary
Mohammad Shahjahani
Masumeh Maleki Behzad

Oncology Reviews

doi 10.4081/oncol.2018.373

Original Research

Published on 23 Sep 2022

Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms

in Cytokines and Soluble Mediators in Immunity

Amanda Fernandes de Oliveira Costa
Leticia Olops Marani
Thiago Mantello Bianco
Adriana Queiroz Arantes
Izabela Aparecida Lopes
Diego Antonio Pereira-Martins
Leonardo Carvalho Palma
Priscila Santos Scheucher
Josiane Lilian dos Santos Schiavinato
Larissa Sarri Binelli

Frontiers in Immunology

doi 10.3389/fimmu.2022.768592

5,097 views
5 citations

Original Research

Published on 08 Feb 2021

JAK2V617F Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages

in Cytokines and Soluble Mediators in Immunity

Rongqing Li
Na Sun
Xin Chen
Xueqin Li
Jie Zhao
Wanpeng Cheng
Hui Hua
Masahiko Fukatsu
Hirotaka Mori
Hiroshi Takahashi

Frontiers in Immunology

doi 10.3389/fimmu.2020.589048

7,910 views
18 citations

Original Research

Published on 26 Oct 2021

A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm

in Hematologic Malignancies

Haotian Zhang
Amar Yeware
Sandy Lee
Huichun Zhan

Frontiers in Oncology

doi 10.3389/fonc.2021.753465

3,846 views
2 citations

Original Research

Published on 08 Jul 2022

Inhibition of Osteoblast Differentiation by JAK2V617F Megakaryocytes Derived From Male Mice With Primary Myelofibrosis

in Cancer Molecular Targets and Therapeutics

Aikaterini Karagianni
Shinobu Matsuura
Louis C. Gerstenfeld
Katya Ravid

Frontiers in Oncology

doi 10.3389/fonc.2022.929498

5,938 views
2 citations

Review

Published on 08 Jan 2026

Targeting the JAK2V617F mutant hematopoietic microenvironment in myeloproliferative neoplasm

in Hematopoiesis and Stem Cells

Amar Yeware

Frontiers in Hematology

doi 10.3389/frhem.2025.1694867

1,522 views

Case Report

Published on 27 Feb 2023

Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies

in Neuroendocrine Science

Lívia Sira
Noémi Zsíros
László Bidiga
Sándor Barna
Zsolt Kanyári
Edit B. Nagy
Nicolas Guillaume
Damian Wild
Katalin Rázsó
Szilvia Andó

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1095815

4,216 views
6 citations

Original Research

Published on 24 Oct 2023

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

in Hematologic Malignancies

Kathrin Olschok
Bianca Altenburg
Marcelo A. S. de Toledo
Angela Maurer
Anne Abels
Fabian Beier
Deniz Gezer
Susanne Isfort
Katrin Paeschke
Tim H. Brümmendorf

Frontiers in Oncology

doi 10.3389/fonc.2023.1277453

7,611 views
14 citations

Original Research

Published on 14 May 2025

Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study

in Hematologic Malignancies

Long Chang
Wen-Xin Li
Hao Cai
Jian Li
Ming-Hui Duan

Frontiers in Oncology

doi 10.3389/fonc.2025.1586839

3,763 views
1 citation

Original Research

Published on 21 Jul 2023

Cigarette smoke stimulates clonal expansion of Jak2V617F and Tet2-/- cells

in Hematologic Malignancies

Gajalakshmi Ramanathan
Jane H. Chen
Nitya Mehrotra
Tiffany Trieu
Aaron Huang
Eduard Mas
Jessica E. Monterrosa Mena
Bishop Bliss
David A. Herman
Michael T. Kleinman

Frontiers in Oncology

doi 10.3389/fonc.2023.1210528

5,963 views
13 citations

Review

Published on 17 Oct 2023

Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?

in Hematology

Giovanni Fulvio
Chiara Baldini
Marta Mosca
Antonello di Paolo
Guido Bocci
Giuseppe Alberto Palumbo
Emma Cacciola
Paola Migliorini
Rossella Cacciola
Sara Galimberti

Frontiers in Medicine

doi 10.3389/fmed.2023.1254868

7,464 views
4 citations

Case Report

Published on 19 Aug 2024

Case report: A case of effective treatment of primary myelofibrosis with nodular panniculitis using ruxolitinib combined with corticosteroids

in Hematologic Malignancies

Guzailinuer Wufuer
Jia-Lin Zhao
Qin Huang
Ainiwaer Babayi
Dilinuer Abudureyimu
Min Mao
Ming-hui Duan

Frontiers in Oncology

doi 10.3389/fonc.2024.1412021

2,696 views

Brief Research Report

Published on 21 Sep 2022

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression

in Cancer Molecular Targets and Therapeutics

Alessandro Malara
Cristian Gruppi
Margherita Massa
Maria Enrica Tira
Vittorio Rosti
Alessandra Balduini
Giovanni Barosi

Frontiers in Oncology

doi 10.3389/fonc.2022.987643

2,922 views
5 citations

Perspective

Published on 18 Oct 2024

The CHIP-clinic as the catalyst of preventive medicine

in Blood Cancer

Hans Carl Hasselbalch
Vibe Skov
Lasse Kjaer
Trine Alma Knudsen
Christina Schjellerup Eickhardt-Dalbøge
Christina Ellervik
Sabrina Cordua
Anders Lindholm Sørensen
Sarah Friis Christensen
Marie Hvelplund Kristiansen

Frontiers in Hematology

doi 10.3389/frhem.2024.1459154

3,208 views
4 citations

Review

Published on 19 Nov 2021

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors

in Cancer Immunity and Immunotherapy

Daniele Cattaneo
Alessandra Iurlo

Frontiers in Immunology

doi 10.3389/fimmu.2021.750346

11,827 views
16 citations

Articles

Ropeginterferon-alfa2b resolves angina pectoris and reduces JAK2V617F in a patient with clonal hematopoiesis of indeterminate potential: A case report

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance

Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms

JAK2V617F Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages

A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm

Inhibition of Osteoblast Differentiation by JAK2V617F Megakaryocytes Derived From Male Mice With Primary Myelofibrosis

Targeting the JAK2V617F mutant hematopoietic microenvironment in myeloproliferative neoplasm

Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study

Cigarette smoke stimulates clonal expansion of Jak2V617F and Tet2-/- cells

Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?

Case report: A case of effective treatment of primary myelofibrosis with nodular panniculitis using ruxolitinib combined with corticosteroids

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression

The CHIP-clinic as the catalyst of preventive medicine

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors